Document is current
Any future updates will be listed below
-
Authors
Tang, Chunmeng https://orcid.org/0000-0002-2802-208X
Foucher, Juliette
Öijerstedt, Linn
Ombelet, Fouke
Ingre, Caroline
Van Damme, Philip
Van Laere, Koen
De Vocht, Joke
Koole, Michel
-
Funding
Funding for this research was provided by:
FWO (12AQF24N)
KU Leuven (fundamental clinical investigatorship)
KU Leuven (Een Hart voor ALS)
KU Leuven (Laeversfonds voor ALS Onderzoek)
E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders (E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders)
ALS Liga België (ALS Liga België)
- License Information
-
More Information
Article History
Received: 28 June 2025
Accepted: 18 November 2025
First Online: 22 December 2025
Declarations
:
: PVD has served in advisory boards for Biogen, CSL Behring, Alexion Pharmaceuticals, Ferrer, QurAlis, Cytokinetics, argenx, UCB, Muna Therapeutics, Alector, Augustine Therapeutics, VectorY, Zambon, Amylyx, Novartis, Prilenia, Verge Genomics, Sapreme Technologies, Trace Neuroscience, NRG Therapeutics (paid to the institution). PVD has received speaker fees from Biogen and Amylyx (paid to the institution).
